The Effect of Latanoprost vs Timolol on lntraocular Pressure in Patients with Glaucoma and Ocular Hypertension

The objective of this study was to compare the effect on intraocular pressure (IOP) of latanoprost 0.005% once daily with timolol 0.5% twice daily in patients with open angle glaucoma or ocular hypertension. The study was designed as a single-centre, randomised, double-masked parallel-group comparison of latanoprost with timolol after 12 weeks of treatment. 60 patients with open angle glaucoma or ocular hypertension with IOP of at least 22 mm Hg were included. Administration of previous ocular hypotensive medication necessitated a wash-out period of 5 to 21 days before the start of the study treatment. The patients were randomised to treatment with latanoprost 0.005% once daily or timolol 0.5% twice daily. Mean diurnal IOP was measured at baseline and after 6 and 12 weeks of treatment. After 6 weeks of treatment, the diurnal IOP reduction (mean± standard error of the mean [SEM]) in the latanoprost group was 12.1±1.1 mm Hg (41%;p<0.001; analysis of covariance [ANCOVA]) and 8.7 ± 1.1 mm Hg (30%; p < 0.001; ANCOVA) in the timolol group. The difference of 3.4 ± 1.6 mm Hg was statistically significant in favour of latanoprost (p = 0.034; ANCOVA). A 30% reduction or more in mean diurnal IOP was achieved by 71 % of patients in the latanoprost group and by 34% of patients in the timolol group. After 12 weeks of treatment, the diurnal IOP reduction (mean± SEM) in the latanoprost group was 11.1±1.2 mm Hg (39%; p < 0.001; ANCOVA) and 9.1 ± 1.1 mm Hg (32%; p < 0.001; ANCOVA) in the timolol group. Most side effects observed were mild and transient and no serious adverse events were reported. Latanoprost 0.005% administered once daily in the evening was at least as effective as timolol 0.5% twice daily in reducing the mean diurnal IOP after 6 and 12 weeks of treatment. Both medications were well tolerated during the study period.

Download Full-text

A Comparative Analysis of the Efficacy and Safety of fixed Combinations of Latanoprost/Timolol vs Dorzolamide/Timolol in Primary Open Angle Glaucoma or Ocular Hypertension

Journal of Postgraduate Medicine Education and Research ◽

10.5005/jp-journals-10028-1039 ◽

2012 ◽

Vol 46 (4) ◽

pp. 172-176

Author(s):

Sukhsagar Ratol ◽

Rani Walia ◽

Mridu Chaudhry

Keyword(s):

Ocular Hypertension ◽

Primary Open Angle Glaucoma ◽

Fixed Combination ◽

Open Angle Glaucoma ◽

Eye Drops ◽

Open Angle ◽

Once Daily ◽

Group 2 ◽

Diurnal Iop ◽

Group 1

ABSTRACT Background Glaucoma is a leading cause of irreversible blindness. The fundamental problem in medical management of glaucoma is of patient compliance. An ideal drug or a drug combination is needed to slow the progression of this majorly symptomless disease. Aim To compare the efficacy and tolerability of the fixed combination latanoprost and timolol instilled once daily in the evening vs fixed combination of dorzolamide and timolol instilled twice daily in primary open angle glaucoma or ocular hypertension. Materials and methods A 12-week, randomized, open, parallel group study including 50 patients with primary open angle glaucoma or ocular hypertension was conducted at a tertiary care hospital. Patients were randomized to group 1, (fixed combination (FC) latanoprost and timolol eye drops, once daily in evening) and group 2, (FC dorzolamide and timolol eye drops, twice daily). At baseline, 2, 4 and 12 weeks, IOP was recorded at 9 AM and 12 noon. The difference in IOP reduction in two treatment groups from baseline to 12 weeks was the main outcome measure. Results Mean diurnal IOP was similar at baseline for both groups. Mean reduction in IOP from baseline to 12 weeks was 9.92 mm Hg (p = 0.001) in group 1 and 9.22 (p = 0.001) in group 2. The reduction in IOP in both groups 1 and 2 was statistically significant at all time intervals. There was a statistically significant advantage for group 1 at 12 weeks for both time readings (p = 0.013 and 0.002 respectively) as compared to group 2. Conclusion The fixed combination of latanoprost and timolol was more effective than that of dorzolamide and timolol in reducing mean diurnal IOP and both treatments were well tolerated. To confirm further such studies are required. How to cite this article Ratol S, Walia R, Chaudhry M. A Comparative Analysis of the Efficacy and Safety of fixed Combinations of Latanoprost/Timolol vs Dorzolamide/Timolol in Primary Open Angle Glaucoma or Ocular Hypertension. J Postgrad Med Edu Res 2012;46(4):172-176.

Download Full-text

Comparison of a Travoprost BAK-Free Formulation Preserved with Polyquaternium-1 with BAK-Preserved Travoprost in Ocular Hypertension or Open-Angle Glaucoma

European Journal of Ophthalmology ◽

10.5301/ejo.5000001 ◽

2011 ◽

Vol 22 (1) ◽

pp. 34-44 ◽

Cited By ~ 25

Author(s):

◽

Stefano Gandolfi ◽

Tania Paredes ◽

Ivan Goldberg ◽

Michael Coote ◽

...

Keyword(s):

Intraocular Pressure ◽

Ocular Hypertension ◽

Free Group ◽

Benzalkonium Chloride ◽

Open Angle Glaucoma ◽

Open Angle ◽

Once Daily ◽

Lowering Effect ◽

Effective Option ◽

The Difference

Purpose To demonstrate that the intraocular pressure (IOP)–lowering effect of travoprost 0.004% preserved with polyquaternium-1 (travoprost benzalkonium chloride [BAK]-free) is non-inferior to that of travoprost 0.004% preserved with benzalkonium chloride (travoprost BAK) in patients with ocular hypertension or open-angle glaucoma. Methods A total of 371 patients randomly received travoprost BAK-free (n=185) or travoprost BAK (n=186) dosed once daily in the evening for 3 months. Patients were evaluated at 9 AM, 11 AM, and 4 PM at baseline, weeks 2 and 6, and month 3. Intraocular pressure was also evaluated 36 and 60 hours after the month 3 visit. Results Travoprost BAK-free is non-inferior to travoprost BAK. The 95% upper confidence limits for the difference in mean IOP at month 3 (primary efficacy) were 0.5 mmHg, 0.6 mmHg, and 0.5 mmHg, at 9 AM, 11 AM, and 4 PM, respectively. Mean IOP reductions from baseline ranged from 7.6 to 8.7 mmHg in the travoprost BAK-free group and from 7.7 to 9.2 mmHg in the travoprost BAK group. At 36 and 60 hours after the last dose, mean IOP remained 6.8 mmHg and 5.7 mmHg below baseline in the travoprost BAK-free group, vs 7.3 mmHg and 6.0 mmHg in the travoprost BAK group, respectively. The safety profile of travoprost BAK-free was similar to that of travoprost BAK. Conclusions Travoprost BAK-free safely and effectively lowers IOP in eyes with open-angle glaucoma or ocular hypertension. This BAK-free formulation has comparable safety, efficacy, and duration of IOP-lowering effect to travoprost preserved with BAK. Travoprost BAK-free is an effective option for IOP reduction while avoiding BAK exposure.

Download Full-text

Preservative-free versus preserved latanoprost eye drops for reducing intraocular pressure: a non-inferiority phase III randomized, multi-center, single-blind, parallel-group controlled trial

Medical hypothesis discovery and innovation in ophthalmology ◽

10.51329/mehdiophthal1413 ◽

2021 ◽

Vol 9 (4) ◽

Author(s):

Panos Theodosiadis ◽

Anastasios Konstas ◽

Ioannis Halkiadakis ◽

Vasiliki Dimera ◽

Dimitrios Koufakis ◽

...

Keyword(s):

Intraocular Pressure ◽

Ocular Hypertension ◽

Open Angle Glaucoma ◽

Ophthalmic Solution ◽

Phase Iii ◽

Point Estimate ◽

Eye Drops ◽

Open Angle ◽

Parallel Group ◽

Preservative Free

Background: The aim of this study was to test the non-inferiority of preservative-free (PF) latanoprost 50 μg/mL multi-dose ophthalmic solution versus the marketed benzalkonium chloride (BAK)-preserved latanoprost 50 μg/mL ophthalmic solution in patients with open-angle glaucoma and patients with ocular hypertension. Methods: This was a prospective, national, randomized, multi-center, observer-blind, parallel-group controlled clinical trial. Patients were randomized to receive either PF or BAK-preserved latanoprost once daily for 12 weeks. The primary endpoint was the change in intraocular pressure (IOP) at 8:00 AM in the affected eye between the end of the treatment (week 12) and the baseline (week 0). Secondary measurements were taken at weeks 2 and 6, with IOP being recorded at 8:00 AM, 12:00 PM, and 4:00 PM. Results: A total of 158 patients were included in the per protocol (PP) population (77 in the PF latanoprost treatment arm and 81 patients in the BAK-preserved latanoprost treatment arm). PF latanoprost was non-inferior to BAK-preserved latanoprost in reducing IOP at 8:00 AM in the study eye from the baseline (week 0) to the end of the treatment (week 12). The point estimate of the between-treatment difference was 0.1 mmHg (95% confidence interval: -0.646, 0.847). Mean between-group differences in IOP reduction from the baseline to each of the secondary measurements were also similar between the two treatment arms. The two treatments were well tolerated and had comparable adverse event profiles. Conclusions: PF latanoprost was non-inferior to BAK-preserved latanoprost in reducing IOP in patients with open-angle glaucoma or ocular hypertension. Both treatments were well tolerated.

Download Full-text

Latanoprost versus timolol gel-forming solution once daily in primary open-angle glaucoma or ocular hypertension

Canadian Journal of Ophthalmology ◽

10.3129/can.j.ophthalmol.06-096 ◽

2007 ◽

Vol 42 (1) ◽

pp. 75-81 ◽

Cited By ~ 1

Author(s):

Paul Harasymowycz ◽

Cindy M.L. Hutnik ◽

Marcelo Nicolela ◽

William C. Stewart

Keyword(s):

Ocular Hypertension ◽

Primary Open Angle Glaucoma ◽

Open Angle Glaucoma ◽

Open Angle ◽

Once Daily

Download Full-text

Comparison of the efficacy and safety of bimatoprost (0.03 %) and travoprost (0.004 %) in patients with primary open angle glaucoma

Nepalese Journal of Ophthalmology ◽

10.3126/nepjoph.v5i1.7831 ◽

2013 ◽

Vol 5 (1) ◽

pp. 75-80 ◽

Cited By ~ 5

Author(s):

Ashish Chander ◽

H Kapoor ◽

S Thomas

Keyword(s):

Intraocular Pressure ◽

Side Effect ◽

Primary Open Angle Glaucoma ◽

Open Angle Glaucoma ◽

Open Angle ◽

Efficacy And Safety ◽

Once Daily ◽

The Mean ◽

To Receive

Purpose: To compare the efficacy and safety of bimatoprost (0.03 %) and travoprost (0.004 %) in patients with primary open angle glaucoma (POAG). Subjects and methods: Patients with POAG were randomized to receive either bimatoprost or travoprost once daily. Detailed ocular examination was done and intraocular pressure (IOP) was measured at 9.00 am, 1.00 pm and 4.00 pm at the baseline and at 1, 2, 4, 6 and 12 weeks of therapy. Results: A total of 31 patients were analysed. The patients were randomly divided into two groups (Bimatoprost group = 16; Travoprost group = 15). Both the groups had a statistically significant reduction from the baseline IOP at all follow up visits at 9.00 am, 1.00 pm and 4.00 pm. The mean IOP decreased from a baseline of 25 ± 2.32 mm Hg to 15.93 ± 1.79 mm Hg after 12 weeks in the bimatoprost group (p < 0.001), and from 24.2 ± 1.60 mm Hg to 16.53 ± 1.56 mm Hg in the travoprost group (p < 0.001). A better mean reduction of IOP was obtained with bimatoprost than with travoprost at the end of the study at 12 weeks (p = 0.03). Mild ocular redness was the commonest side effect in both the groups but was not significant in either group. Conclusion: Both drugs lowered IOP effectively but bimatoprost showed a greater reduction in the mean IOP than did travoprost at 12 weeks and both are safe for ocular use. Nepal J Ophthalmol 2013; 5(9):75-80 DOI: http://dx.doi.org/10.3126/nepjoph.v5i1.7831

Download Full-text

Efficacy and Safety of a Fixed Combination of Travoprost 0.004%/Timolol 0.5% Ophthalmic Solution Once Daily for Open-Angle Glaucoma or Ocular Hypertension

American Journal of Ophthalmology ◽

10.1016/j.ajo.2005.02.058 ◽

2005 ◽

Vol 140 (2) ◽

pp. 242.e1-242.e11 ◽

Cited By ~ 54

Author(s):

Joel S. Schuman ◽

Gregory J. Katz ◽

Richard A. Lewis ◽

J. Charles Henry ◽

Sushanta Mallick ◽

...

Keyword(s):

Ocular Hypertension ◽

Fixed Combination ◽

Open Angle Glaucoma ◽

Ophthalmic Solution ◽

Open Angle ◽

Efficacy And Safety ◽

Once Daily

Download Full-text

Comparison of the efficacy and safety of fixed combination travoprost/timolol and dorzolamide/timolol in patients with primary open-angle glaucoma and ocular hypertension

Srpski arhiv za celokupno lekarstvo ◽

10.2298/sarh1308441b ◽

2013 ◽

Vol 141 (7-8) ◽

pp. 441-446 ◽

Cited By ~ 2

Author(s):

Nikola Babic ◽

Veljko Andreic ◽

Aleksandar Miljkovic ◽

Desanka Grkovic ◽

Predrag Jovanovic

Keyword(s):

Ocular Hypertension ◽

Primary Open Angle Glaucoma ◽

Fixed Combination ◽

Open Angle Glaucoma ◽

Group Versus ◽

Open Angle ◽

Conjunctival Hyperemia ◽

Randomized Clinical Study ◽

Diurnal Iop

Introduction. Combining two medications in one bottle may improve compliance by reducing the time required to administer drops and the frequency of the total number of medication bottles. Objective. To compare the efficacy of reduced intraocular pressure (IOP) and safety of fixed combination travoprost 0.004%/timolol 0.5% vs. fixed combination dorzolamide 2%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension. Methods. Prospective randomized clinical study included 60 patients divided into 2 groups. Follow-up was done at day 14 and 45 and month 3. IOP measurements were taken at each follow-up examination at 8 am, 10 am and 4 pm. Results. Both fixed combinations reduced IOP significantly compared to initial values at all follow-ups (p<0.001). Mean pooled IOP at all visits and time points was slightly lower in the travoprost/timolol group compared with the dorzolamide/timolol group (16.13 mmHg vs. 16.15 mmHg). Mean IOP reduction from baseline ranged from -7.46 mmHg to -9.92 mmHg in the travoprost/timolol group and from -6.93 mmHg to -8.93 mmHg for the dorzolamide/timolol group. Mean (?standard error of the mean) reduction in diurnal IOP from baseline to 3rd month was 8.96?2.79 in the travoprost/timolol group versus 8.07?2.91 in patients receiving dorzolamide/timolol fixed combination (p=0.196). The most frequent treatment-related adverse events were conjunctival hyperemia in the travoprost/timolol group, and dry eye and foreign body sensation in the dorzolamide/timolol group. Conclusion. Travoprost/timolol fixed combination was slightly more effective than dorzolamide/timolol fixed combination in reducing mean diurnal IOP. Travoprost/timolol group resulted in an IOP reduction for up to 1.07 mmHg higher than dorzolamide/timolol group. Both fixed combinations were well tolerated and safe.

Download Full-text

A comparison of the efficacy and tolerability of brimonidine and latanoprost in adults with open-angle glaucoma or ocular hypertension: A three-month, multicenter, randomized, double-masked, parallel-group trial

Clinical Therapeutics ◽

10.1016/s0149-2918(01)80150-8 ◽

2001 ◽

Vol 23 (12) ◽

pp. 1969-1983 ◽

Cited By ~ 26

Author(s):

Harvey B DuBiner ◽

Michael Mroz ◽

Aron M Shapiro ◽

Monte S Dirks

Keyword(s):

Ocular Hypertension ◽

Open Angle Glaucoma ◽

Open Angle ◽

Parallel Group ◽

Parallel Group Trial ◽

Group Trial

Download Full-text

A 12-week Study Evaluating the Efficacy of Bimatoprost 0.03% in Patients with Pseudoexfoliative and Open-Angle Glaucoma

European Journal of Ophthalmology ◽

10.1177/112067210901900412 ◽

2009 ◽

Vol 19 (4) ◽

pp. 594-600

Author(s):

Marco Ciancaglini ◽

Paolo Carpineto ◽

Luca Agnifili ◽

Mario Nubile ◽

Lisa Toto ◽

...

Keyword(s):

Open Angle Glaucoma ◽

Open Angle ◽

Serious Adverse Events ◽

Pseudoexfoliative Glaucoma ◽

Target Values ◽

Drug Naïve ◽

Target Pressure ◽

To Receive ◽

Diurnal Iop

Purpose To evaluate the control of diurnal intraocular pressure (IOP) and the safety profile of bimatoprost in pseudoexfoliative glaucoma (PXG) compared to primary open angle glaucoma (POAG). Methods A prospective, observer-masked, nonrandomized study was performed. Seventy consecutive patients with either POAG (35 eyes) or PXG (35 eyes) drug-naive for glaucoma were assigned to receive bimatoprost 0.03% once daily for 12 weeks. Diurnal IOP was measured at baseline and after 12 weeks at three time points (8 AM, noon, and 4 PM). Main outcomes were diurnal IOP control and achievement of target IOP (CIGTS criteria). Mean diurnal IOP, hour-by-hour IOP measurements, and safety, including serious adverse events, were also evaluated. Results A significant IOP reduction from baseline was found in both groups (p<0.001). Mean and hour-by-hour IOP differences between groups were not statistically significant (NS). The observed IOP values and percentages of IOP reduction were 17.0 mmHg (31.5%) and 16.4 mmHg (31.9%) in PXG and POAG eyes, respectively; the differences were not statistically significant. Six eyes (1 POAG and 5 PXG, respectively) responded with a <20% IOP reduction (NS). Twenty-seven POAG (77.1%) and 23 PXG (65.7%) eyes achieved target IOP. Consequently, 20 eyes (8 POAG and 12 PXG, respectively) were classified as unable to achieve the IOP target values (NS). Conclusions Bimatoprost was effective and safe in lowering IOP both in open angle and pseudoexfoliative glaucoma, achieving target pressure in most patients. However, long-term efficacy in PXG must be evaluated.

Download Full-text